E
ELEVATION ONCOLOGY INC
NASDAQ: ELEV (Elevation Oncology, Inc.)
Kemas kini terakhir: 4 jam lalu0.350
0.01 (2.91%)
| Penutupan Terdahulu | 0.340 |
| Buka | 0.344 |
| Jumlah Dagangan | 585,662 |
| Purata Dagangan (3B) | 1,458,719 |
| Modal Pasaran | 20,728,294 |
| Harga / Buku (P/B) | 0.460 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 2 May 2025 - 5 May 2025 |
| EPS Cair (TTM) | -0.810 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 66.87% |
| Nisbah Semasa (MRQ) | 19.40 |
| Aliran Tunai Operasi (OCF TTM) | -39.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.38 M |
| Pulangan Atas Aset (ROA TTM) | -29.86% |
| Pulangan Atas Ekuiti (ROE TTM) | -78.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Elevation Oncology, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Nilai 35% | -0.7 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.7 |
| Masa 35% | 0.6 |
| AI Technical info | NA |
| Osilator Teknikal info | 0.0 |
| Purata Bergerak Teknikal info | 1.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.4% |
| Persetujuan Tonggak | ×0.79 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 0.2 |
| Skor Akhir | -0.03 |
|
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.36% |
| % Dimiliki oleh Institusi | 57.31% |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |